News

Press Release: FDA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

October 12, 2014

“Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The U.S. FDA orphan designation comes after the European Medicines Agency (EMA) orphan status approval of AMY-101 for the same indication, less than two months ago.”

To read entire press release: www.fiercepharma.com

 
Amyndas features in ΒΗΜΑ, on of the widest-read Greek national Sunday newspapers

September 7, 2014

ΒΗΜΑ Science, the science news source from Greek Sunday newspaper BHMA, on September 7, 2014, posted an extended and informative interview of Amyndas pharmaceuticals founder, Dr. John Lambris. In this article, which aimed at communicating the results of Dr. John Lambris’ scientific research to the public, Amyndas’ promising new drugs and their potential therapeutic applications are presented for the first time in a widely-read national Greek newspaper, conveying the profound impact that these new therapies can have for patients and health care systems internationally. The article created significant interest, with its wide readers’ audience commending and responding enthusiastically, hoping that these new therapies to be brought to patients soon.

To read article (in Greek): www.tovima.gr

 
Press Release: EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

August 27, 2014

“EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria.”

To read entire press release: www.prlog.org

 
Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters

July 17, 2014

Amyndas’ recent developments caught the interest of the international press, with BioWorld publishing an article about Amyndas on July 17. In this article, Amyndas is presented as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders, that could be more potent than other complement inhibitors. The article is titled “Two- pronged Amyndas targets complement-based anti-inflammatories.”

To read article: www.bioworld.com

 
Press Release: Penn team identifies promising new target for gum disease treatment

May 20, 2014

“University of Pennsylvania researchers have been searching for ways to prevent, halt and reverse periodontitis. In a report published in The Journal of Immunology, they describe a promising new target: a component of the immune system called complement. Treating monkeys with a complement inhibitor successfully prevented the inflammation and bone loss that is associated with periodontitis, making this a promising drug for treating humans with the disease.”

To read entire press release: www.upenn.edu

 
Press Release: Penn study shows way to make treatment of rare blood disorder more affordable and effective

February 26, 2014

“A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system – called “complement” — that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.”

To read entire press release: www.uphs.upenn.edu

 
Press Release: Penn immunologist to develop drugs for renal disease

February 21, 2014

“John Lambris, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the department of pathology and laboratory medicine at Penn’s Perelman School of Medicine, is part of an $8 million European Union FP7 grant, which has been awarded to a consortium of academic institutions and the biotech company called Amyndas Pharmaceuticals (based on Penn technology developed in the Lambris lab).”

To read entire press release: www.upenn.edu

 
BioCentury: Amyndas developing super compstatins for complement-mediated disorders

February 10, 2014

On February 10, 2014, in the article entitled “Amyndas: Complement shutdown,” Amyndas Pharmaceuticals was presented in BioCentury as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders that could be more potent than other complement inhibitors.

To read article: www.biocentury.com